We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.
BLCM

Delisted

BLCM was delisted on the 1st of June, 2023.

Back to rankings

28 hedge funds and large institutions have $2.13M invested in Bellicum Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less capital invested

Capital invested by funds: $2.22M → $2.13M (-$90K)

7% less funds holding

Funds holding: 30 → 28 (-2)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
28
Holders Change
-2
Holders Change %
-6.67%
% of All Funds
0.48%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$4.4K
2
Osaic Holdings
Osaic Holdings
Arizona
+$2.55K
3
Renaissance Technologies
Renaissance Technologies
New York
+$382
4
Citigroup
Citigroup
New York
+$159
5
LPL Financial
LPL Financial
California
+$32

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$95.9K
2
Citadel Advisors
Citadel Advisors
Florida
-$13K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$9.84K
4
BFM
Boothbay Fund Management
New York
-$6.04K
5
UBS Group
UBS Group
Switzerland
-$3K

BLCM Hedge Fund Activity: Q3 2022 in Review

28 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2022, worth a combined $2.13M — down 4.1% from $2.22M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BLCM and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 4 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $4.4K. The largest seller was Ikarian Capital, cutting an estimated $95.9K.

  • 28 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2022, down from 30 in Q2 2022.
  • Funds reported $2.13M of Bellicum Pharmaceuticals, Inc. stock for Q3 2022, down 4.1% quarter-over-quarter.
  • 1 fund opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2022 and 3 closed out, a net change of -2 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2022 was Tower Research Capital (TRC), an estimated $4.4K added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2022 was Ikarian Capital, an estimated $95.9K sold.

Based on aggregated 13F filings for Q3 2022.